ProCE Banner Activity

How I Plan to Use Trastuzumab Deruxtecan and Tucatinib in My Practice

Clinical Thought
Are you prepared to use trastuzumab deruxtecan and tucatinib for your patients with HER2+ MBC and disease progression on standard-of-care HER2-targeted therapies?

Released: January 21, 2020

Expiration: January 19, 2021

Share

Faculty

Heather McArthur

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen

Faculty Disclosure

Primary Author

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Heather McArthur, MD, MPH, has disclosed that she has received funds for contracted research from Bristol-Myers Squibb and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Genentech, Genomic Health, Merck, Pfizer, and Puma.